scribed in frame, and coded mutant FLT3 with a long JM
Introduction chronic myeloid leukemia or lymphoid malignancies. 38 In some AML patients, the internal tandem duplication of the FLT3 is a member of the receptor tyrosine kinase (RTK) class FLT3 gene (FLT3/ITD) was detected not at diagnosis but at III, which includes KIT, FMS and PDGFR. [1] [2] [3] [4] Structurally, RTK relapse, suggesting that FLT3/ITD may clinically be associated class III has an extracellular region composed of five immunowith leukemia progression. globulin-like domains, a single transmembrane region, a jux-AML is a heterogeneous leukemia as to molecular altertamembrane (JM) domain, two tyrosine kinase domains (TK1 ations such as chromosomal translocations. 26 In this study, in and TK2) spaced by a kinase insert (KI) domain, and a Corder to characterize FLT3/ITD, we chose acute promyelocytic terminal domain. FLT3 is preferentially expressed in hematoleukemia (APL), a molecularly distinct subtype of AML dispoietic stem cells in addition to brain, placenta and liver. [2] [3] [4] [5] tinguished by t (15;17) . 27 We analyzed the FLT3 gene and its The ligand to FLT3 (FL) is expressed as a membrane-bound or message in samples from 74 patients, and compared the soluble form by bone marrow stroma cells, and stimulates the clinical features and prognosis between patients with and stem cells by itself or cooperatively with other cytokines. [6] [7] [8] [9] without FLT3/ITD. Thus, a FL-FLT3 ligand receptor interaction supposedly plays an important role in hematopoiesis. On the other hand, while most clinical samples from acute myeloid leukemia (AML) and
Patients and methods acute lymphoblastic leukemia (ALL) express FLT3, exogenous FL stimulates the proliferation of AML cells rather than ALL Patients cells.
10-14 Some leukemia-lymphoma cell lines reportedly express both FLT3 and FL, 15, 16 suggesting a possible autocrine Seventy-four newly diagnosed patients with APL, who were or paracrine stimulation. 17 treated according to the AML92 study of the Japan Adult LeuMolecular alteration of cytokine receptors in neoplasm has kemia Study Group from January 1992 to January 1995, were studied. 28 APL was morphologically diagnosed according to the FAB classification. The 15/17 translocation was detected Correspondence: T Naoe, Department of Infectious Diseases, Nagoya in all 74 patients using either karyotype analysis, reverse-blot analysis. Details of these molecular analyses were described previously. 29, 30 Degree of disseminated intravascular coagulation (DIC) was evaluated according to the published criteria. 31 The AML-92 protocol was described previously. 28 Briefly, all-trans retinoic acid (ATRA) (45 mg/m 2 ) was administered orally until complete remission (CR) when peripheral white blood cell (WBC) counts were below 3.0 × 10 9 /l. If the counts were over 3.0 × 10 9 /l, daunorubicin (DNR) at 40 mg/m 2 for 3 days and behenoyl cytosine arabinoside (BHAC) at 200 mg/m 2 were added for 5 days. If the leukemia cell counts exceeded 1.0 × 10 9 /l during the ATRA therapy, DNR at 40 mg/m 2 for 3 days and BHAC at 200 mg/m 2 for 5 days were added to avoid hyperleukocytosis. After reaching CR, three courses of consolidation chemotherapy and six courses of maintenance/intensification chemotherapy were given.
Amplification of the FLT3 gene and sequencing High-molecular weight DNA was extracted from APL cells as previously described. 29 Because the previous papers showed that the location of FLT/ITD was restricted to exons 11 and 12, 25, 38 genomic PCR amplification was performed using the primers, 11F, 5′-GCAATTTAGGTATGAAAGCCAGC, and 12R, 5′-CTTTCAGCATTTTGACGGCAACC-3′ (Figure 1a) . The PCR mixture contained 500 ng of genomic DNA, 50 pmol of 11F and 12R primers, 0.2 mM of each deoxynucleotide triphosphate, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 0.001% gelatin (wt/vol), 50 M tetramethylammonium chloride and 2.5 units of Taq polymerase (Amplitaq; Perkin Elmer, Norwalk, CT, USA). Denaturing, annealing, and exten- Chatsworth, CA, USA), and cloned into the pMOSBlue T-vector (Amersham, Buckinghamshire, UK) according to the manufacturer's recommendations. Ten recombinant colonies were chosen and cultured in LB medium. Plasmid DNA was prepared using a QIAprep spin plasmid miniprep kit (Qiagen Inc) and both strands were sequenced using fluoresceinStatistical methods conjugated -21M13 and T7 primers on a DNA sequencer (377; Applied Biosystems, Foster City, CA, USA).
Difference in age was analyzed by the Wilcoxon rank-sum test. The natural logarithm of peripheral WBC counts, peripheral leukemia cell counts, platelet counts, fibrinogen and LDH were used to adjust for skewness in the distribution of these RT-PCR of the FLT3 transcript variables, and were analyzed with the Wilcoxon rank-sum test. The male to female ratio, morphology (typical M3 or variant M3), and CR rate were evaluated by the Fisher's exact test Total cellular RNA was prepared from APL cells using the guanidium isothiocyanate/cesium chloride method as prefor 2 × 2 tables. The frequency of moderate and severe DIC (grade 2 and 3) was also compared using the Fisher's exact viously described. 30 Complementary DNA (cDNA) was synthesized from 10 g of total RNA using random hexamer pritest. Survival was calculated for the first day of therapy to death. mers (Gibco BRL, Gaithersburg, MD, USA) and Moloney murine leukemia virus reverse transcriptase (SuperScript II; CR duration was calculated from the date of CR to relapse. Disease-free survival (DFS) for patients who had achieved CR Gibco BRL) according to the manufacturer's recommendations. From a total of 20 l cDNA, 2 l was amplified with was measured from the date of CR to relapse or death. Overall survival and DFS curves were computed according to the the primers R5, 5′-TGTCGAGCAGTACTCTAAACATG-3′, and 12R, 5′-CTTTCAGCATTTTGACGGCAACC-3′ (Figure 1a) .
Kaplan-Meier method. The log-rank test and the generalized Wilcoxon test were used to compare the overall survival and Abnormal-sized transcripts were cloned and sequenced as described above.
DFS curves for FLT3/ITD-positive and -negative groups. Tyr residue and the clinical parameters. WBC counts as well as peripheral leukemia cell counts were correlated with the patients, longer PCR products were detected in addition to germ line bands (Figure 1b) . In two of the 15 patients, ampliincreased number of Tyr residue (Figure 3) . The FLT3 gene is located on chromosomal band 13q12, 1 fied germ line bands were more weakly observed than each abnormal band, suggesting a loss of normal allele. By but this band was affected in none of our patients by cytogenetic analysis, although three patients had additional sequence analysis the longer PCR products revealed that they contained duplicated fragments within the FLT3 gene. The chromosomal changes. duplicated fragment size was from 18 to 90 (median 48) bp. In patients 3, 7, 10 and 15, 3′ part of exon 11 with 5′ part of intron 11 was tandemly duplicated. In the remaining patients, Clinical response and prognosis in both types of APL only a part of exon 11 was duplicated. Extranucleotides (2, 3 and 2 nucleotides) were inserted between the duplications in The CR rates for APL patients with and without FLT3/ITD were 14/15 (93.3%) and 47/59 (79.7%), respectively (P = 0.20) patients 3, 7 and 9, respectively. In all 15 APL patients with FLT3/ITD, the longer FLT3 transcripts were detected as (Table 1) . At a median follow-up period of 26 months, 18 of 61 expected (Figure 1c ). Sequence analysis confirmed that FLT3/ITD coded in frame transcripts (amino acid sequence are patients who had achieved CR relapsed. The predicted 3-year overall survival was 52.5% for the FLT3/ITD-positive group shown in Figure 2 ). Although the FLT/ITD varied in size and location, they involved either Y591 or Y599. However, the (n = 15) and 59.6% for the FLT3/ITD-negative group (n = 59) (P = 0.67 by log-rank test, P = 0.71 by generalized Wilcoxon TK1 domain, which is located downstream to codon 608, was not significantly involved in FLT3/ITD. All duplicated fragtest). The predicted 3-year DFS was 50.0% for the FLT3/ITDpositive group (n = 14) and 74.1% for the negative group ments contained one to four Tyr residues except for M810 which had been reported by Nakao et al. 25 (n = 47) (P = 0.34 by log-rank test, P = 0.49 by generalized Wilcoxon test). The overall survival and DFS curves according to the presence of FLT3/ITD are shown in Figure 4 . These data suggested that the presence of FLT3/ITD did not significantly Relationship between FLT3/ITD and clinical features influence the CR rate and prognosis of APL. To clarify clinical differences between patients with and without FLT3/ITD, clinical variables at the first diagnosis were compared (Table 1) . WBC counts and peripheral leukemia Discussion cell counts were significantly higher in the FLT3/ITD-positive patients (P Ͻ 0.0001). Serum LDH level was higher in the In this study, we characterized the FLT3/ITD regarding its sequence and clinical significance. The most notable finding FLT3/ITD-positive patients (P = 0.04). Plasma fibrinogen level was lower in FLT3/ITD-positive patients (P = 0.04). Moderate of FLT3/ITD was the manner of somatic mutation. To date, somatic internal tandem duplication associated with neoand severe DIC (grade 2 and 3) tended to be more frequent in FLT3/ITD-positive patients (P = 0.095). However, no other plasm has been reported in the MLL gene in AML with trisomy 11. 32 The duplicated fragment consisted of more than 1000 bp clinical parameters were associated with the presence of
Results

FLT3
Figure 2
Amino acid sequences duplicated by FLT3/ITD. At the top, amino acid sequence of the JM and TK1 domains are presented. The TK1 domain sequence are underlined. Samples from patients 3, 7 and 9 had non-coded amino acids due to reading intron sequence, change of the boundary sequence between the gene duplication and nucleotides insertion, respectively. M series sequences were according to Nakao et al. covering several exons, and its biological role in leukemia remains unclear. Another example is the TK domain of the trk gene, which was activated by the head-to-tail duplication.
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However, this duplication was identified only in cultured cells transfected with DNA. In FLT3/ITD, a small DNA fragment from 18 to 90 bp was duplicated within a restricted genomic region, indicating a new mechanism of gene alterations associated with neoplasm. Sequence analysis showed that FLT3/ITD was always transcribed in frame and involved Y591 or Y599, whereas TK domain was not significantly affected. According to the previous data, 25 YFY at codons 589 to 591 also seemed to be another target for FLT3/ITD. In comparing FLT3 and PDGF, the Y589 of FLT3 corresponds to Y579 of PDGFR, which is known to be phosphorylated by ligand-binding. 34 Since the phosphorylated Y579 of PDGF binds with the SH2 domain of the src family, 34 the Y589 of FLT3 might be similarly associated with signal transduction. On the other hand, significance of the Y597 and Y599 is unclear. The Y597 of FLT3 corresponds to Y589 of PDGF which is not phosphorylated in vitro. However, if Y589 of FLT3 is phosphorylated by TK of FLT3, Y597 and Y599 may be consecutively phosphorylated by the FLT3-src family complex. 35 Thus, one FLT3/ITD might amplify the FLT3 signal pathway rather than activate FLT3 itself without ligand stimulation.
Another possibility is that FLT3/ITD disrupts a negative regulatory domain of signal transduction. In FMA3 murine mastocytoma cell line, c-kit gene carried a deletion of 21 bp
Figure 3
Relation between the number of increased Tyr residues encoding TQLPYDH at codons 573 to 579 in its JM domain. 24 and peripheral leukemia cell counts.
The mutant KIT was constitutively activated and abrogated the IL-3 dependency of the transfected cells. Since codons 573 to 579 of murine KIT corresponds to REYEYDL at codons 595 to are reportedly rare in APL. 37 Furthermore, if the mutated FLT3 is abnormally activated, FLT3-signal pathway could be potential targets for new therapy. activity. In one case sequenced previously, 25 forming activity, phosphorylation and signal transduction. the CR duration is shorter. 36 In this study, however, we could gle cytogenetic abnormality. 27 Mutations of ras and p53 genes
